Fusion protein PP13138R and application thereof in tuberculosis prevention

• Main Authors: LIU YINPING, XUE YONG, WANG JIE, CHENG PENG, JIANG FAN, ZHUANG LI, GONG WENPING
• Format: Patent
• Language: Chinese; English
• Published: 14.07.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention discloses a fusion protein PP13138R and an application of the fusion protein PP13138R in tuberculosis prevention. Specifically disclosed is a fusion protein comprising HTL, CTL and B cell epitopes, PorB, PADRE and RS-09, which are connected in series. 34 epitopes aiming at the mycobacterium tuberculosis are screened, and the mycobacterium tuberculosis epitopes have the characteristics of good immunogenicity and antigenicity, no toxicity, no sensitization, high population coverage rate and the like. An auxiliary peptide PADRE is further added to improve the immunogenicity of the vaccine, and PorB and RS-09 are added to endow the vaccine with a targeted delivery function. In-vitro experiments prove that the PP13138R can stimulate human peripheral blood mononuclear cells to generate immune response and is a dominant protective antigen. The PP13138R serving as the vaccine has the advantages of simple preparation method, low cost, high yield, higher safety and the like. The invention has great value